Department of Hematology, Zhongnan Hospital of Wuhan University
Department of Hematology at Zhongnan Hospital of Wuhan University was established in the 1970s. After decades of development, it now possesses three wards with 105 open beds and 14 laminar flow beds, treating over 15,000 outpatients, 3,000 inpatients. Department of Hematology is equipped with an independent hematology laboratory and has advanced medical technology and equipment. It can carry out various routine and special examinations, including cell morphology/pathology, immunology, cytogenetics, molecular biology, etc, with the ability to detect, collect, isolate and freeze hematopoietic stem/progenitor cells. The scope of diagnosis and treatment includes various hematological diseases such as anemia, bleeding diseases, and hematological malignancies (including leukemia, lymphoma, multiple myeloma, etc.). Recently, novel strategies such as TMI-based conditioning regimen HSCT, Cord blood cell micro-transplantation, Cord blood cell transplantation and Plasma-free plasmapheresis and Double filtration plasmapheresis (DFPP) have been carried out. Meanwhile, multiple clinical trials and technical cooperation of professional alliance with local hospitals have been undertaken, endowing the Department with a reputation in China. The Department is currently being granted as multiple centers: National Key Clinical Specialty Construction Project (Hematology and Oncology), National Construction Project for Improving the Diagnosis and Treatment of Intractable Diseases (hematology oncology), Hematology Base of National Drug Clinical Trial Institution, Standardized Training Base for Chinese Resident Physician in Hematology, Volunteer Stem Cell Collection Base of Chinese Marrow Donor Program, Standardized Operation Training Base of Blood Component Separation and Cell Therapy in Central China, Postdoctoral Station of Hematology of Wuhan University, Transplantation Medical Center (Stem Cell Transplantation) of Wuhan University, Umbilical Cord Blood Stem Cell Transplantation Center, Diagnosis and Treatment Center for MDS/MPN and Chronic Disease Management Center for Multiple Myeloma.
After several generations of efforts, the Department of Hematology in Zhongnan Hospital has formed a discipline echelon with reasonable age structure, educational level and professional title structure. There are currently 21 physicians and 9 technicians in the department, including 2 doctoral instructors, 12 of which with doctoral degrees and 9 with at least 1 year of overseas workstudy experience. The department also has 5 postdoctoral fellows, 10 doctoral students, and 15 master students receiving education in hematology. It undertakes theoretical teaching and clinical teaching for medical undergraduates, masters and doctoral students, while incubating post-doctoral mobile station and authorized points for doctoral and masters degrees. It also undertakes various scientific research funds at various levels, including 1 National Key Project, 11 National Natural Science Foundation, more than 30 funds from Hubei Province, Wuhan City, and Wuhan University, and a number of national-level teaching programs and MOOC teaching projects. Staff of the department have published more than 200 academic papers in domestic and foreign academic journals as first/corresponding authors, several monographs of Renwei Edition as editor-in-chiefco-editors, and obtained several patents. The department has established long-term and stable medical cooperation relations with blood centers and scientific research institutions of many famous hospitals in China and abroad, including the United States, France, Canada and Hong Kong, providing a reliable guarantee for the development of new diagnosis and treatment technologies. In recent years, the scientific research strength of the department has grown tremendously. In 2020, the department’s STEM ranking of Chinese hospitals in terms of scientific and technological value has risen to No.22 among the nation’s other hospitals.
Professor Fuling Zhou, chief and director of the Department of Hematology, has engaged in basic and clinical research on hematological diseases for decades. She is specialized in the research on the pathogenesis and therapeutic targets of acute myeloid leukemia (AML), and has achieved internationally-leading research results, where she originally proposed the antioxidant pathway for the treatment of AML, which has been approved as a national invention patent and widely applied. Professor Zhou, shortlisted in the 2020 National Top 100 Academic Influence of Hematology Experts, has been invited to present at domestic and foreign academic conferences for more than 50 times. Her scientific research results have also been presented internationally such as the American Society of Hematology (ASH) and the European Hematology Conference (EHA). Additionally, she serves as the review committee of the National Natural Science Foundation of China, and has been repeatedly honored, including the 2020 Wuhan University "Medical Take-off Plan" Outstanding Contribution Award. She presided 1 national key project, 4 National Natural Science Foundation projects, 12 provincial and municipal projects with approved funds of over 23 million yuan. In the past five years, she has published more than 80 high-level SCI papers as the firstcorresponding author with highest single SCI impact factor of 41 and highest single citation of 102 times. She has published 5 monographs as the editor-in-chief and acquired 12 national invention patents.